Skip to main navigation menu Skip to main content Skip to site footer

Vol. 13 No. 01 (2026)
International Multidisciplinary Journal for Research & Development

Articles

ANTIPLATELET PROPERTIES OF MUMIE: AN IN VITRO STUDY OF PLATELET AGGREGATION

Published 2026-01-29

  • Zagrutdinov Fanil Faridovich

Zagrutdinov Fanil Faridovich
Andijan State Medical Institute, Department of Pharmacology, Clinical Pharmacology, and Medical Biotechnology.

Abstract

Platelet aggregation plays a central role in hemostasis and thrombosis, and modulation of platelet function is an important therapeutic target. Natural substances with antiplatelet properties are of increasing scientific interest. Platelet aggregation was studied in vitro using platelet-rich plasma. Aggregation was induced by sodium adenosine diphosphate (ADP). Mumie was tested at concentrations of 0.1 and 0.3 mg/mL. Heparin, acetylsalicylic acid, ε-aminocaproic acid, and sodium lagosol were used as reference compounds. Platelet aggregation time was recorded, and results were expressed as mean ± SEM. Statistical significance was assessed in comparison with control samples. Mumie significantly prolonged platelet aggregation time at both tested concentrations, indicating a marked inhibition of platelet aggregation (p < 0.05). The effect was concentration-dependent and comparable to that of acetylsalicylic acid and heparin. Heparin demonstrated the strongest antiaggregatory effect at higher concentrations, while ε-aminocaproic acid showed moderate inhibition. Sodium lagosol exhibited the weakest antiplatelet activity.

Keywords

Mumie, platelet aggregation, antiplatelet activity, hemostasis, heparin, acetylsalicylic acid, ADP-induced aggregation.

PDF

References

  1. Qi Z, Kelley E. The WHO Traditional Medicine Strategy 2014-2023: A perspective. Science. 2014;346:S5-S6.
  2. “WHO Traditional Medicine Strategy 2014-2023”. World Health Organization Retrieved 2014-04-20. 2013.
  3. Shahriari M, Zare F, Nimrouzi M. The Curative Role of Bitumen in Traditional Persian Medicine. Acta Med Hist Adriat. 2018;16(2):283-92.
  4. Olivieri MF, Marzari F, Kesel AJ, Bonalume L, Saettini F. Pharmacology and psychiatry at the origins of Greek medicine: The myth of Melampus and the madness of the Proetides. J Hist Neurosci. 2017;26(2):193-215.
  5. Shirbeigi L ZA, Naghizadeh A, Alizadeh Vaghasloo M. The Concept of Temperaments in Traditional Persian Medicine. Trad Integr Med. 2017;2(3):143-56.
  6. Frolova N, Kiseleva L, Tatiana. Chemical composition of mumijo and methods for determining its authenticity and quality (a review). Pharma Chem J. 1996;30(8):543-7.
  7. Agarwal SP, Khanna R, Karmarkar R, Anwer MK, Khar RK. Shilajit: a review. Phytother Res. 2007;21(5):401-5.
  8. Verma A, Kumar N, Gupta L, Chaudhary S. Shilajitin Cancer Treatment: Probable Mode of Action. Int J Pharmaceutic Bio Arch. 2016;7(1):12-6.
  9. Stohs SJ, Singh K, Das A, Roy S, Sen CK. 12-Energy and Health Benefits of Shilajit. In: Bagchi D, editor. Sustained Energy for Enhanced Human Functions and Activity. Academic Press; 2017. p. 187-204
  10. Ghosal S, Lal J, Singh SK, Goel RK, Jaiswal AK, Bhattacharya SK. The need for formulation of Shilajit by its isolated active constituents. Phytother Res. 1991;5(5):211-6
  11. Trivedi N, Mazumdar B, Bhatt J, Hemavathi K. Effect of shilajit on blood glucose and lipid profile in alloxaninduced diabetic rats. Indian J Pharmacol. 2004;36(6):373-6.
  12. Загрутдинов, Ф. Ф., Мамадалиев, Ш. И., & Болтабоева, Д. Ф. (2024). Влияние Среднеазиатских Видов Мумиё на диурез и натрий урез у Крыс. Open Herald: Periodical of Methodical Research, 2(5), 12-14.

Downloads

Download data is not yet available.